EyeGene Inc (185490) — Capital Reinvestment Ratio

Latest as of September 2023: 8.77x

EyeGene Inc (185490) has a Capital Reinvestment Ratio of 8.77x as of September 2023, meaning it reinvests 9% of its operating cash flow (₩541.79 Million) in capital expenditures (₩4.75 Billion). See 185490 free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.

Capital Reinvestment Ratio

8.77x

Capex / Operating Cash Flow

Operating Cash Flow

₩541.79 Million

KRW

Capital Expenditures

₩4.75 Billion

KRW

Data as of

Sep 2023

Most recent filing

Annual Capital Reinvestment Ratio for EyeGene Inc (None–None)

Year-by-year Capital Reinvestment Ratio for EyeGene Inc from None to None. For live market cap and broader valuation context, see 185490 market cap overview.

Year	Reinvestment Ratio	Operating CF (KRW)	Capital Expenditures	YoY Change

Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow